Ricoh Company, Ltd. has entered into a significant non-exclusive licensing agreement with ERS Genomics Limited, granting access to foundational CRISPR/Cas9 genome editing technology patents in the USA and Japan. This collaboration underscores the importance of CRISPR/Cas9 as a breakthrough gene-editing tool, facilitating precise modification of targeted genome sequences essential for various applications, particularly in drug discovery research.
CRISPR/Cas9 Genome Editing License Agreement
The agreement follows Ricoh’s acquisition of Elixirgen Scientific, Inc. in 2022, a company renowned for its expertise in rapid and efficient differentiation of human induced pluripotent stem (iPS) cells and mRNA design, production, and management. By combining these core technologies with CRISPR/Cas9 genome editing, Ricoh aims to revolutionize drug discovery by predicting drug mechanisms and enhancing the speed and efficiency of mRNA design.
Ricoh’s integration of Elixirgen Scientific’s technologies with CRISPR/Cas9 holds immense promise for creating highly reliable disease models, including those for rare diseases. This advancement is expected to streamline drug development processes, leading to shorter timelines and increased success rates. With a focus on personalized medicine and leveraging digital and artificial intelligence technologies, Ricoh is committed to accelerating drug development research and contributing to advancements in regenerative medicine. Moreover, Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive representative of ERS Genomics in Japan, further expanding the reach of CRISPR/Cas9 technology in the region.
